Evidence map›Paper›PMID 41867385›Full record

ArticleJournal of blood medicine2026

Development and Validation of a Novel Thrombosis Prediction Model for Adult Immune Thrombocytopenia (ITP-THROMBO).

Huiling Yan, Xing Hu, Lijun Zhu, Yuhan Jiang, Chen Luo, Mengya Lv, Yan Wang, Juan Tong, Changcheng Zheng

Abstract read
In one paragraph

Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huiling YanDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Xing HuDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Lijun ZhuDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Yuhan JiangDepartment of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wuhu, People's Republic of China.
Chen LuoDepartment of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wuhu, People's Republic of China.
Mengya LvDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Yan WangDepartment of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
Juan TongDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.ORCID 0000-0002-1567-3625
Changcheng ZhengDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.ORCID 0000-0002-1976-6415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by bleeding, yet paradoxically, it can also predispose patients to thrombotic events; therefore, investigating high-risk factors for thrombosis in ITP patients and developing a predictive model is essential. Patients and Methods: A total of 1112 patients were diagnosed with ITP between January 2018 and December 2023. Excluding 216 patients under the age of 18, a total of 896 adult ITP patients were included in this study (of whom 101 developed thrombosis). Patients were randomly allocated to the training set (n=628) and validation set (n=268) in a 7:3 ratio. Results: Atrial fibrillation, peripheral vascular disease, venous thromboembolism history, pneumonia < 1 month, cerebrovascular events history, and D-dimer levels were identified as predictive factors for thrombosis in ITP patients. The six factors formed 57 unique combinations, providing robust predictive power for thrombosis in ITP under different clinical scenarios. In the training set, the area under the curve (AUC) for the nomogram was 0.656 (95% CI: 0.578-0.735) to 0.931 (95% CI: 0.902-0.960) and the AUC in the validation set was 0.539 (95% CI: 0.425-0.653) to 0.893 (95% CI: 0.828-0.957). The calibration curve demonstrated good concordance between the model's predicted probabilities and actual observed probabilities, and the decision curve analysis indicated that the model had significant clinical utility. Conclusion: This cohort study developed a simple and practical predictive model (ITP-THROMBO) for estimating thrombosis risk in ITP patients; this model facilitates rapid identification of ITP patients at high thrombotic risk, enabling timely decision-making support for personalized treatment planning.

Indexed as

immune thrombocytopeniaITPprediction modelthrombosis

Identifiers

PMID41867385
PMCPMC13003822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.